NOTE: All in-article links open in a new tab.

April 2020 MAC Talk

Published on 

Monday, April 20, 2020

 | Recovery Auditor 
 | Coding 
 | Documentation 

Medical Review Administrative Relief Related to the Novel Coronavirus (COVID-19) Pandemic

Palmetto GBA has posted the following Notice on their website:

The Centers for Medicare & Medicaid Services (CMS) has authorized nationwide waivers under §1812(f) of the Social Security Act retroactive to March 1, 2020, for those impacted by COVID-19. Medicare Fee-For-Service (FFS) operations will implement the following policies and procedures for all claims, not just for the COVID-19 diagnoses.

 

Additional Documentation Requests (ADRs)

  • For ADRs that have already been issued, Medicare contractors will release the claims for payment and not issue claim denials; providers should not respond to any pending claims as all claims will be released for relief efforts.
  • Any claims auto-denied for non-response of an ADR from March 1, 2020, until March 26, 2020, will have the denial reversed and allow payment if an appeal has not been filed. If an appeal has been filed, normal appeals processes will be followed.
  • As of March 26, 2020, future ADRs will not be sent until further notice from CMS

 

Targeted Probe and Education (TPE)

  • All current TPE reviews and associated edits are suspended and selected claims released for payment
  • MACs will allow TPE medical review education sessions to be rescheduled upon provider request

Note: Providers must resume compliance with normal Medicare fee-for-service rules and regulations as soon as they are able. The waivers or modifications a provider was operating under are no longer available after the termination of the emergency period.

 

April MAC Talk: The Local Scene

 

March 17th, 2020: Palmetto GBA JM Posts TPE Progress Updates

It seems a little ironic that in March Palmetto GBA JM began releasing Targeted Probe and Educate (TPE) Progress Updates. Medical Review specific articles include the dates of services reviewed, the volume of probes performed, the charge denial rates, top denial reasons, tips for preventing denials, next steps, and references.

In regards to “Next Steps,” Palmetto GBA indicates that Providers found to be non-compliant (major risk category/denial rate of 21–100%) at the completion of TPE Probe 1 will advance to Probe 2 at least 45 days from completion of the 1:1 post probe education call date. Palmetto GBA offers education at any time for providers. Providers do not have to be identified for TPE to request education.

Following is a list of the specific TPE articles released to date by Palmetto GBA JM:

  • March 17, 2020: DRG 682/683 Renal Failure with MCC/CC,
  • March 17, 2020: DRG 470 – Major Joint Replacement,
  • March 18, 2020: Inpatient Rehab Facility A0604, B0604, C0604 and D0604,
  • March 18, 2020: DRG 885 Psychoses,
  • March 19, 2020: Therapeutic Exercise 97110,
  • March 19, 2020: Skilled Nursing Facility (SNF),
  • March 23, 2020: Rituximab J9310/J9312,
  • March 23, 2020: Pegfilgrastim J2505,
  • March 23, 2020: Neuromuscular Re-education – 97112,
  • March 23, 2020: Manual Therapy – 97140,
  • March 23, 2020: Infliximab J1745,
  • March 23, 2020: HBO Therapy G0277,
  • March 23, 2020: DRG 291 Heart Failure and Shock with MCC and DRG 292 Heart Failure and Shock with CC,
  • March 23, 2020: Denosumab J0897, and
  • March 23, 2020: Bevacizumab J0935.

Links to all of the articles can be found on Palmetto GBA’s JM Target Probe and Educate webpage.

 

March 20, 2020: First Coast Revises Articles A52571 and A57778

Article A52571: Self-Administered Drug Exclusion List

Effective May 3, 2020, First Coast (JN) has added the following drugs to the self-administered drug (SAD) list:

  • Tremfya® (guselkumab) (J1628), and
  • Stelara® (ustekinumab) subcutaneous (J3357).

This announcement includes a link to their entire list of SADs.

Article A57778: Billing and Coding Intravenous Immune Globulin

First Coast has added the new FDA approved drug Panzyga® (immune globulin intravenous, human – IFAS) (HCPCS codes C9399 and J1599) to the CPT®/HCPCS Codes/Group 1 Paragraph:/Group 1 codes:” and “ICD-10 Codes that Support Medical Necessity/Group 1 Paragraph:” section.

This change is effective for claims processed on or after March 16, 2020, for services rendered on or after August 2, 2018.

 

March 24, 2020: Palmetto GBA Daily Newsletter: Self-Administered Drug Exclusion List Article Changes

Palmetto GBA posted information about revisions made to their Self-Administered Drug Exclusion List

Article A53066.

These changes will be effective 4/20/2020. They encourage providers to share this information with their staff.

  • Revision 23 (R23): Under Excluded CPT/HCPCS Codes – Table Format the previous revision (R22) that added HCPCS Code J3358 – Stelara®, ustekinumab for intravenous injection, 1mg should be disregarded as this code was inadvertently added. HCPCS code J3557 – Stelara®, ustekinumab for subcutaneous injection, 1mg has been added.

 

March 25, 2020: Palmetto GBA JJ Posts TPE Progress Updates

A little over a week after Palmetto GBA released TPE Progress Updates for Jurisdiction M they began posting findings for Jurisdiction J. Review specific articles follow the same format as articles released for JM. Following is a list of specific TPE articles released to date by Palmetto GBA JJ:

  • March 25, 2020: HBO Therapy G0277,
  • March 25, 2020: JJ Part A Skilled Nursing Facility (SNF),
  • March 25, 2020: Therapeutic Exercise 97110,
  • April 3, 2020: DRG 885 Psychoses; and
  • April 3, 2020: DRG 470 Major Joint Replacement,
  • April 10, 2020: Manual Therapy 97140,
  • April 10, 2020: Inpatient Rehabilitation Facility (IRF) A0604-D0604
  • April 10, 2020: Pegfilgrastim J205,
  • April 10, 2020: DRGs 291 and 292: Heart Failure and Shock with MCC and with CC,
  • April 11, 202: Rituximab J9310,
  • April 11, 2020: Infliximab J1745,
  • April 11, 2020: Denosumab J0897, and
  • April 11, 2020: Bevacizumab J9035.

Links to all of the articles can be found on Palmetto GBA’s JJ Target Probe and Educate webpage.

 

March 30, 2020: CGS Posts Notice Medical Review Update

On January 31, 2020, Secretary Azar of the Department of Health & Human Services (HHS) declared a nationwide public health emergency.  On March 13, 2020, Secretary Azar authorized waiver and modifications under §1135 of the Social Security Act retroactive to March 1, 2020. CGS understands the effect of COVID-19 on our provider community. In response to questions received regarding Medical Review Additional Document Requests (ADRs) and Targeted Probe and Educate (TPE) activity, at this time, CGS has temporarily suspended TPE reviews. Our medical review and provider outreach and education staff will continue to be available to conduct education sessions and provide answers to questions to ensure that providers understand regulatory guidelines to prevent improper payment. To reschedule a TPE educational session, request an educational session related to medical review topics, or for medical review general TPE questions please contact us at one of the email addresses below or contact the appropriate provider contact center (PCC) at: https://www.cgsmedicare.com/help/index.html.

 

April 1, 2020: NGS News COVID-19 Update: Important Information Regarding Part A and B Second-Level Appeals
NGS provided the following “information at the request of the Qualified Independent Contractor (QIC), C2C Innovative Solutions, Inc. (C2C). C2C conducts second-level Medicare Part A and B Fee-for-Service claims appeals submitted in Jurisdiction K Part A and B as well as Jurisdiction 6 home health and hospice for New York, New Jersey, Puerto Rico and the U.S. Virgin Islands. If you appeal to C2C as the Part A and B East QIC, they are limiting their on-site mail room operations in response to the COVID-19 public health emergency. During this public health emergency, providers and Medicare beneficiaries falling into the above categories are encouraged to submit new second-level Medicare appeals and related correspondence via fax or the electronic portal. For additional information including the QIC fax numbers and a link to their portal, please visit the C2C website.”

 

April 6, 2020: NGS Posts Update Regarding Pricing of HCPCS G2066

NGS News and Alerts

On 3/12/2020 NGS posted an article on their website regarding a fee adjustment for HCPCS G2066 (Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results).

While NGS recognizes its authority to periodically review and adjust pricing as warranted of any “Contractor Priced“ codes, the adjustment in payment for HCPCS G2066 will not go into effect during this PHE, as scheduled on April 24, 2020.

HCPCS G2066 was created by the CMS for 2020 to replace the retired code of CPT 93299. Therefore, the fee for G2066 will remain the same as the prior 2019 fee for CPT 93299.

At such time as the PHE is deemed over, HCPCS G2066 will be reviewed for pricing based on other MAC fees; a thorough review of this service; and further input from stakeholders.

 

April 8, 2020: Palmetto GBA Claims Payment Issue: Medically Unlikely and Procedure-to-Procedure Edit Updates Due to COVID-19

Palmetto GBA identified the following Issue on April 3, 2020:

As a result of the CMS expansion of telehealth services in response to COVID-19, CMS updated certain Medically Unlikely Edits (MUEs) and Procedure-to-Procedure (PTP) edits for CPT and HCPCS codes, retroactive to January 1, 2020. Palmetto GBA advises that they will implement the CMS replacement files and adjust affect claims with dates of service on or after March 6, 2020. Additionally, any appeals already started by Palmetto GBA that related to MUE or PTP denials will be prioritized for review using the replacement files for claims with dates of service on or after March 6, 2020.

 

April 9, 2020: NGS Daily News: A Message from Our Medical Review Team: Targeted Probe and Educate Medical Reviews
In the wake of the public health emergency related to COVID-19, National Government Services (NGS) is in the process of pausing Targeted Probe and Educate (TPE) Medical Reviews. At this time, they are unable to provide additional clarity on when or how TPE reviews will resume, but will share information as it’s made available. They will work with providers who previously scheduled educational sessions to reschedule them.

NGS is contacting providers to let them know claims were released and there is no need to respond to an additional development request (ADR) for medical records. Effective 3/1/2020, claims that auto-denied for nonresponse or late response to the ADR will be reversed and allowed for payment unless an appeal has already been filed. In that case, the appeal will follow the normal appeals process.

NGS’ dedicated email address remains available for questions specific to medical reviews

 

April 9, 2020: Palmetto GBA Update: MACs to Host Multi-jurisdictional Contractor Advisory Committee (CAC) Meeting Regarding Facet Joint & Medical Nerve Branch Procedures on May 28, 2020 from 1-3 p.m. CT

Due to the COVID-19 Pandemic, the decision has been made to hold the meeting via Teleconference/Webinar ONLY. All other information remains the same.

The purpose of the meeting is to obtain advice from CAC members and subject matter experts (SMEs) regarding the strength of published evidence on Facet Joint and Medial Nerve Branch Procedures. In addition to discussion, the CAC and SME panel will vote on pre-distributed questions. The public is invited to attend as observers.

The meeting will be hosted by seven Medicare Administrative Contractors and will be held via Teleconference/Webinar. There will be a panel of experts discussing the Facet Joint and Medial Nerve Branch Procedures. CAC panels do not make coverage determinations, but MACs benefit from their advice.

Complete details will be available by May 14, 2020 (background material, questions, and agenda).

Link to Announcement:
https://www.palmettogba.com/palmetto/providers.nsf/DocsR/JJ-Part-A"BMYQLA2250

 

April 13, 2020: WPS J8A Medical Review (MR) Targeted Probe & Educate (TPE) Quarterly Update

WPS provided the common errors identified by their Medical Review staff throughout the first quarter of 2020. Specific for hospitals was the following guidance regarding wound care.

  • Wound Care (CPT 11042): Denials for Documentation Not Supporting Sharp Debridement: WPS reminds Providers that documentation should provide a clear rationale for the excisional debridement. Additionally, the documentation should include a certified plan of care that includes the potential to heal and goals. The WPS Local Coverage Determination (LCD) L37228outlines coverage criteria for wound care.

 

April 13, 2020: WPS eNews: Inpatient Psychiatric Facility (IPF) – CERT Errors

A WPS Announcement indicated that the Comprehensive Error Rate Testing (CERT) Contractor has assessed for errors for IPF services and found that in most cases there was missing documentation to support payment based on Medicare guidelines. The announcement details information that should be submitted in a response to a Medicare request and provides a link to additional information in Chapter 2: Inpatient Psychiatric Hospital Services of the Medicare Benefit Policy Manual.

 

April 13, 2020: OIG Releases Report : An Estimated 87 Percent of Inpatient Psychiatric Facility Claims with Outlier Payments Did Not Meet Medicare’s Medical Necessity or Documentation Requirements

The OIG focus for this audit was claims resulting in outlier payments with an objective of determining whether Inpatient Psychiatric Facilities (IPFs) complied with Medicare coverage, payment, and participation requirements. OIG Findings from the 160 sampled claims:

  • 25 claims did not meet Medicare medical necessity requirements,
  • 142 claims had missing or inadequate medical record elements, including physician certification, and
  • 12 of the 142 claims did not clearly support that the IPF had protected the patient’s right to make informed decisions regarding care.

Ultimately, the OIG estimated that Medicare overpaid IPFs $93 million for FYs 2014 and 2015 for stays that were non-covered or partially non-covered and resulted in outlier payments. 

 

April 16, 2020: CGS Announces Retirement of LCD L34093: Chemotherapy and Biologicals

  • Effective June 7, 2020: CGS will be retiring LCD L34093: Chemotherapy and Biologicals
  • Effective June 8, 2020: LCD L34093 will be replaced with Article A58113: Off-Label Use of Anti-Cancer Drugs and Biologicals
  • CGS Notes in the announcement that, “This is a change from how we currently handle chemotherapy and biological drugs. While there will no longer be a local policy in place with attached billing and coding articles, we will be using the coverage indications as listed in the Centers for Medicare & Medicaid Services (CMS) Internet Only Manual (IOM) 100-02, Chapter 15, section 50.4.1 and 50.4.5 which is the basis for the current policy. CGS will cover these types of drugs based on FDA label indications and for off label use if listed in one of the five CMS approved compendia’s (NCCN, Micromedex Drug DEX, Lexi-Drugs, AHFS, or Clinical Pharmacology).”
  • You can read the entire announcement at:   https://www.cgsmedicare.com/parta/pubs/news/2020/04/cope16807.html

 

April 17, 2020: First Coast eNews: TPE Announcement

“Targeted probe and educate (TPE) reviews have been temporarily postponed due to the public health emergency (PHE) declared as a result of the 2019 novel coronavirus (COVID-19). We encourage providers to focus on patient care and defer discussions related to these reviews after the PHE. First Coast will reach out to providers after the pandemic to offer education based upon prior reviews. In the event providers would like to receive education during this time, we are prepared to provide educational sessions. Please feel free to reach out to the nurse assigned to your case to arrange an educational call.”

Article Author: Beth Cobb, RN, BSN, ACM, CCDS
Beth Cobb, RN, BSN, ACM, CCDS, is the Manager of Clinical Analytics at Medical Management Plus, Inc. Beth has over twenty-five years of experience in healthcare including eleven years in Case Management at a large multi-facility health system. In her current position, Beth is a principle writer for MMP’s Wednesday@One weekly e-newsletter, an active member of our HIPAA Compliance Committee, MMP’s Education Department Program Director and co-developer of MMP’s proprietary Compliance Protection Assessment Tool.

This material was compiled to share information.  MMP, Inc. is not offering legal advice. Every reasonable effort has been taken to ensure the information is accurate and useful.